Evenity (Romosozumab) for Women 65 and Older: Activity, Exercise, and Daily Life Considerations

What Romosozumab Actually Does to Your Bones Before You Start Moving

Romosozumab works differently from every other osteoporosis drug on the market. It blocks sclerostin, a protein produced by osteocytes (your bone's own cells) that normally puts the brakes on new bone formation. By inhibiting sclerostin, Evenity simultaneously increases bone formation and decreases bone resorption during its 12-month treatment period. The FRAME trial showed a 6.9% increase in lumbar spine BMD and a 25% reduction in new vertebral fractures at 12 months versus placebo, published in the New England Journal of Medicine in 2017.

This dual mechanism matters for your activity planning because you are gaining structurally stronger bone while still receiving injections, not after the course is complete.

Why the 12-Month Window Is Not Negotiable

The bone-forming effect of romosozumab is time-limited. Sclerostin inhibition and the anabolic signal diminish significantly after 12 months, which is why the FDA-approved course is fixed at 12 monthly injections. Missing injections delays the timeline but does not extend the anabolic window.

For women 65 and older, this window is the highest-return period for pairing drug therapy with the right physical activities. Bone responds to mechanical loading, and romosozumab's anabolic signal appears to amplify the bone-forming response to mechanical stress in animal models. The clinical implication is that weight-bearing activity during treatment is likely more productive than the same activity outside of it.

What "High Fracture Risk" Means at 65 and Beyond

Most women starting romosozumab at 65 or older qualify because of a T-score of -2.5 or lower at the spine or hip, a prior osteoporotic fracture, or a FRAX 10-year major fracture probability above the country-specific threshold. ACOG's guidance on osteoporosis in postmenopausal women notes that approximately 1 in 2 women over 50 will sustain an osteoporosis-related fracture in their lifetime. At 65 and beyond, hip fracture risk accelerates sharply with each decade.

Understanding your baseline fracture risk helps contextualize which activities are appropriate and which need modification.

Activity and Exercise During Romosozumab Treatment

The right exercise prescription during romosozumab therapy is weight-bearing, progressive, and specific to your current fracture risk. There is no evidence that physical activity interferes with the drug's mechanism of action. The goal is to provide the mechanical stimulus that helps bone cells take advantage of the anabolic signal.

Weight-Bearing Exercise: The Non-Negotiable Foundation

Weight-bearing exercise means your skeleton is bearing your body weight against gravity. Walking, stair climbing, low-impact aerobics, dancing, heel drops, and modified Tai Chi all qualify. A Cochrane systematic review found that exercise interventions involving weight-bearing activity and resistance training improved BMD at the lumbar spine and femoral neck in postmenopausal women, making exercise a complementary intervention rather than a substitute.

For women 65 and older on romosozumab, aim for at least 30 minutes of weight-bearing activity on most days. You do not need to be athletic or pain-free to benefit. A 10-minute walk three times per day counts.

Resistance Training: Building the Muscle That Protects the Bone

Muscle contraction pulls on bone and triggers osteoblast activity. Resistance training at moderate intensity (50-70% of your one-repetition maximum, or simply "moderately challenging") two to three times per week targets the hip abductors, quadriceps, and back extensors, the muscles that most directly protect fracture-prone sites.

Chair-based resistance exercises with light dumbbells or resistance bands are appropriate for women who have already experienced a vertebral or hip fracture. Avoid loaded spinal flexion exercises (crunches, toe-touches) if you have a documented vertebral compression fracture, as these increase anterior vertebral stress.

What to Avoid or Modify

Not all movement is helpful. High-impact activities like running on hard surfaces, high-intensity jump training, or contact sports carry meaningful fall and fracture risk for women 65 and older with osteoporosis. This is not a permanent restriction; it reflects the reality that a fragility fracture during your treatment window would interrupt therapy and offset gains.

Activities that involve significant trunk rotation under load (heavy golf swings, competitive tennis groundstrokes) should be discussed with your provider and your physical therapist before continuing. The goal is risk reduction, not immobility.

Fall Prevention: The Most Clinically Important Activity Consideration

Romosozumab builds bone. Falls break it. For women 65 and older, fall prevention is as important as the drug itself.

Your Fall Risk Profile Changes With Age

The CDC reports that approximately 36 million falls occur among older adults in the United States each year, and 32,000 of those falls result in death. Women fall more frequently than men, partly because postmenopausal bone loss creates a wider gap between bone strength and fall-force. The combination of lower muscle mass (sarcopenia accelerates after 60), balance impairment, and polypharmacy compounds the picture.

If you are on romosozumab because you have already had a fracture, your risk of a second fall-related fracture is meaningfully higher than baseline. The ARCH trial, which compared romosozumab followed by alendronate versus alendronate alone in 4,093 postmenopausal women with prior vertebral fracture, showed a 48% reduction in new vertebral fractures with the romosozumab sequence. But that benefit requires staying upright.

Practical Fall-Prevention Steps During Romosozumab Therapy

Review your medications with your prescriber. Sedating antihistamines, benzodiazepines, certain blood pressure drugs, and sleep aids all raise fall risk. Ask specifically whether any of your current medications should be adjusted.

Home safety modifications reduce fall risk by roughly 26% in high-risk older adults when implemented systematically. Remove loose rugs, install grab bars in the bathroom, improve lighting in stairwells, and keep frequently used items at waist height. These are free or low-cost interventions that your provider can refer you for through an occupational therapy assessment.

Tai Chi has the strongest evidence base among balance interventions for older women. A meta-analysis published in the Annals of Internal Medicine found that Tai Chi reduced fall rates by 20% in older adults compared with control groups. Community-based classes are widely available and appropriate for most women 65 and older.

Vision and Vestibular Checks

Uncorrected vision impairment is one of the five most modifiable fall-risk factors in older women. If you have not had an eye exam in the past year, schedule one. Bifocals and progressive lenses can distort depth perception on stairs. Vestibular dysfunction, which is common after age 65 and often underdiagnosed in women, responds well to vestibular rehabilitation therapy when identified.

Daily Life, Routine Activities, and Practical Logistics on Monthly Injections

Injection Day Logistics

Evenity is administered as two separate subcutaneous injections of 105 mg each (total 210 mg) given consecutively by a healthcare provider, once monthly. You do not inject at home. This means a monthly clinic visit for 12 months. Plan around this: most women find it convenient to pair the appointment with another routine health visit.

Some women experience injection-site reactions (redness, swelling, tenderness) in the 24-48 hours after the injection. These are generally mild and resolve on their own. They should not change your activity level unless the site is significantly swollen or painful.

Arthralgia and Muscle Pain

In clinical trials, arthralgia (joint pain) was reported in approximately 12% of women receiving romosozumab compared with about 10% on placebo. The absolute difference is small, but if you notice new joint discomfort after starting Evenity, report it. Do not assume it is unrelated. For most women, the discomfort is mild and does not require stopping treatment. Acetaminophen or a brief course of an NSAID may help, though discuss NSAID use with your prescriber given cardiovascular considerations.

Driving and Travel

There are no driving restrictions with romosozumab. The cardiovascular black-box warning (see below) does not translate into a day-to-day activity limitation for women who are cardiovascularly stable at baseline. Long-haul travel requires the same precautions as always for women 65 and older: stay hydrated, move your legs regularly, and wear compression stockings on flights longer than four hours.

Vitamin D and Calcium: The Daily Habit That Protects Your Investment

Romosozumab's anabolic effect is blunted by calcium and vitamin D deficiency. Clinical trial participants received daily calcium (500-1,000 mg) and vitamin D (600-800 IU) supplementation throughout the FRAME and ARCH trials. Your prescriber should check your baseline 25-OH vitamin D level and target a serum level above 30 ng/mL. Most postmenopausal women require 1,200 mg of elemental calcium per day from food and supplements combined, and 800-1,000 IU of vitamin D3 daily.

Calcium from food (dairy, fortified plant milks, sardines with bones, leafy greens) is better absorbed and carries less cardiovascular signal than large-dose supplements. Try to meet at least half your daily calcium from diet.

The Cardiovascular Black-Box Warning: What It Means for Active Women

This is the most important safety consideration in daily life planning. Romosozumab carries an FDA black-box warning for myocardial infarction (heart attack), stroke, and cardiovascular death.

Who Should Not Take Romosozumab

You should not receive romosozumab if you have had a heart attack or stroke within the past 12 months. The ARCH trial found a numerically higher rate of serious cardiovascular events in the romosozumab arm versus alendronate arm (2.5% vs. 1.9%) during the 12-month active treatment phase. The FDA label reflects this finding with a class-level boxed warning.

If you have known coronary artery disease, prior stent placement, prior stroke, or peripheral artery disease, a detailed cardiovascular risk-benefit discussion with your prescriber and potentially a cardiologist is required before starting Evenity. This is not a drug to start based on a DEXA scan alone in a woman with significant cardiac history.

Symptoms to Take Seriously During Therapy

Report any chest pain, sudden shortness of breath, new arm or jaw pain, sudden confusion, facial drooping, arm weakness, or sudden severe headache to emergency services immediately. Do not wait until your next injection appointment. These are potential cardiac or stroke symptoms, and the black-box warning exists precisely because the risk is real, if uncommon.

For women who are cardiovascularly healthy at baseline, the absolute risk increase is small. The Menopause Society's 2023 position statement on osteoporosis treatment notes that romosozumab's cardiovascular signal must be weighed against the substantial fracture-risk reduction in women at very high fracture risk.

Pregnancy, Lactation, and Contraception

Romosozumab is contraindicated in pregnancy and is not indicated for use in premenopausal women.

Because the drug's approved indication is postmenopausal osteoporosis, the vast majority of women receiving it are well beyond their reproductive years. Sclerostin plays a role in skeletal development, and animal studies using romosozumab at doses higher than the human therapeutic dose showed fetal harm, including skeletal abnormalities. The FDA prescribing information for Evenity states that there are no adequate and well-controlled studies in pregnant women and that the drug should not be used during pregnancy.

For the rare premenopausal woman being evaluated for romosozumab (for example, in the setting of glucocorticoid-induced osteoporosis or another secondary cause), reliable contraception is required throughout treatment.

Lactation data are not available. Because romosozumab is a monoclonal antibody, transfer into breast milk is possible but likely minimal in the early postpartum period. Again, this is a theoretical concern only, as nearly all clinical use occurs in postmenopausal women for whom lactation is not applicable.

There is no hormonal contraception interaction relevant to postmenopausal women receiving Evenity.

Who This Is Right For (and Who Should Consider Something Else)

Women Most Likely to Benefit

Romosozumab is the right choice for postmenopausal women 65 and older who meet at least one of these profiles:

• T-score of -3.0 or worse at the spine or hip with no recent cardiovascular event
• Prior vertebral fracture and very high FRAX score
• Failed or insufficient response to a bisphosphonate after at least two years of treatment
• Rapid bone loss on denosumab with a need for a stronger anabolic signal before bridging

The WomanRx clinical team uses a practical framework to triage older women who come in asking about bone therapy. We call it the "PACE" screen: Prior fracture, Active cardiovascular risk, Calcium/D sufficiency, and Exercise baseline. A woman with a prior fracture, no active cardiac event in the past year, adequate vitamin D, and at least a walking routine is a strong candidate for romosozumab. A woman with a recent MI, even with a T-score of -3.5, should start with denosumab or a bisphosphonate and revisit romosozumab eligibility at 12 months if cardiovascular stability is established.

Women Who Should Consider Alternatives First

• Heart attack or stroke within the past 12 months: start with denosumab or zoledronic acid
• Women with very mild osteoporosis (T-score between -2.5 and -2.0, no fracture, low FRAX): an oral bisphosphonate is likely sufficient
• Women with severe renal impairment (eGFR <30): the safety data in this group are limited; discuss with your nephrologist

After the 12 Months: Protecting What Romosozumab Built

This section is not optional and not a secondary concern. Stopping romosozumab without transitioning to an antiresorptive drug means losing most of the BMD gain within 12 months.

The FRAME extension data showed that women who transitioned from romosozumab to denosumab for 12 additional months gained a further 2.1% at the lumbar spine and maintained hip gains. Women who did not receive follow-on therapy lost BMD rapidly. The ARCH trial used alendronate as follow-on therapy and showed that the romosozumab-then-alendronate sequence produced greater fracture reduction than alendronate alone across 24 months.

Your follow-on plan should be in place before your last injection, not after. Ask your provider at month 10 which antiresorptive you will transition to and when the first dose is scheduled.

Physical activity remains important after the romosozumab course ends. A study in the Journal of Bone and Mineral Research found that postmenopausal women who maintained structured exercise programs preserved more BMD over three years than sedentary women. The numbers are modest (0.5-1.0% difference per year at the hip), but they compound.

What Your Clinician Should Monitor During Treatment

Standard monitoring during romosozumab therapy includes:

• Blood pressure and cardiovascular symptoms at each injection visit
• Serum calcium (hypocalcemia can occur; severe cases are uncommon but more likely with vitamin D deficiency)
• 25-OH vitamin D level at baseline and at 6 months if the initial level was low
• Repeat DEXA at 12 months (after completing the full course) to document response
• Any new fracture during treatment, which requires reassessment of the treatment plan

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs) are class-level concerns for bone-active therapies. The reported incidence of ONJ with romosozumab in clinical trials was less than 0.1%, which is consistent with the rates seen with denosumab. If you need dental surgery (extraction, implant, or periodontal procedure) during romosozumab therapy, inform both your dentist and your prescribing clinician before scheduling.

Frequently Asked Questions